Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
No Progress for Wholesalers’ Negative Primary Margin on Sales, Single-Product, Single-Price Deals Stagnant: Ryukaikon
No progress was made in FY2014 in respect to the issue of negative primary margins on sales, which are drug wholesalers’ losses on sales without factoring in rebates and allowances, the Ministry of Health, Labor and Welfare (MHLW) said on…
To read the full story
Related Article
- Ryukaikon to Push Single-Product, Single-Price Deals in New Proposal Due Out Summer
June 18, 2015
- Measures Would Be Necessary if Generic Brands Continue to Increase Due to Joint Development: MHLW Official Jo
June 18, 2015
- Wholesalers’ Negative Primary Margin on Sales Widens Slightly in First Half of FY2014: Ryukaikon
December 11, 2014
- Ryukaikon Members Hail High Price Settlements, but Fret over Fallout from Penalty Fee Cuts
December 11, 2014
Related LEXICON
-
Medical Fee Cut Rule for Low Price Settlement Rates, Penalty Fee Cuts for Low Price Settlement Rates未妥結減算ルールMay 9, 2014
-
April 19, 2012
REGULATORY
- CEA Expansion Could Make Drug Price Premiums a Liability: JPMA Official
October 16, 2026
- Nipro’s Stemirac Nears 1st Full Nod Conversion for Regenerative Therapy
October 16, 2026
- Japan Set to Compile Support Measures to Secure MCMs by Year-End
October 15, 2026
- Japan to Weigh Necessary Measures for FY2027 Revision: PM
October 15, 2026
- Japan Eyes Multi-Year Funding to Secure MCMs: Takaichi
October 14, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…